DDInter1271 DDInter1676
Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and other beta blockers are generally not first line therapies as many patients are first treated with thiazide diuretics. Nebivolol was granted FDA approval on 17 December 2007.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Nebivolol {u} (Compound) treats {v} (Disease) hypertension
Nebivolol {u} (Compound) binds {v} (Gene) ADRB2
Nebivolol {u} (Compound) causes {v} (Side Effect) Headache
Nebivolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium oxide
Nebivolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium carbonate
Nebivolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Physostigmine
Nebivolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Nebivolol {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Nebivolol {u} may lead to a major life threatening interaction when taken with {v} Dyphylline
Nebivolol (Compound) treats hypertension (Disease)
Nebivolol (Compound) binds ADRB2 (Gene)
Nebivolol (Compound) causes Headache (Side Effect)
Nebivolol may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Nebivolol may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Nebivolol may lead to a major life threatening interaction when taken with Fingolimod
Nebivolol may lead to a major life threatening interaction when taken with Dyphylline